Tarsus Pharmaceuticals, Inc. (TARS) — Insider Trading

AI-Powered SEC Filing Analysis

← All TARS filings
Latest Insider Trading Filed: 2026-01-14

Key Insights

  • The reporting person, Katherine Goodrich, exercised 2,233 restricted stock units (RSUs) on 12/15/2025, indicating their continued ownership and vesting of company equity.
  • The RSUs have a 3-year vesting schedule, with additional tranches vesting in 2026 and 2027, aligning the reporting person's incentives with long-term company performance.
  • The reporting person's direct ownership of Tarsus Pharmaceuticals, Inc. (TARS) shares increased to 2,233 following the RSU exercise, suggesting they maintain a meaningful stake in the company.
Filing tone (AI): Positive
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-01-14. In the app, any new 10-K, 10-Q or 8-K is analyzed the moment you open it.

Download on theApp Store Get it onGoogle Play
Get it on Google Play Open in app →

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.